Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary prophylaxis after CMV disease in kidney transplant patients guided by γδ T-cell monitoring
2017-002912-15Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of valganciclovir in cytomegalovirus disease (CMV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Cumulative incidence of virologic CMV recurrence at 1 year. Started Sep 2017; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2017-002912-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002912-15.